Journal article

BAX-Mutated Clonal Hematopoiesis in Patients on Long-Term Venetoclax for Relapsed/Refractory Chronic Lymphocytic Leukemia

Piers Blombery, Ella R Thompson, Xiangting Chen, Tamia Nguyen, Mary Ann Anderson, David Alan Westerman, John F Seymour, Constantine S Tam, Michael A Dengler, David CS Huang, Andrew Wei, Andrew W Roberts

Blood | American Society of Hematology | Published : 2020


Venetoclax (Ven) is an effective element of treatments for chronic lymphocytic leukemia (CLL) with high response rates observed in the upfront and relapsed/refractory (R/R) settings. In addition to inducing apoptosis in CLL cells, Ven also induces apoptosis within normal and malignant myeloid lineage populations (accounting for its efficacy in the treatment of acute myeloid leukemia). We investigated the effects of Ven outside the target tumor compartment in patients (pts) with CLL receiving long-term continuous Ven and make the novel observation of the development of BAX-mutated clonal hematopoiesis in this heavily pre-treated patient group. 92 pts with CLL receiving continuo..

View full abstract